These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 145518

  • 21. Granulomatous hepatitis as a late complication of BCG immunotherapy.
    Flippin T, Mukherji B, Dayal Y.
    Cancer; 1980 Oct 15; 46(8):1759-62. PubMed ID: 7427878
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma.
    Tan JK, Ho VC.
    J Dermatol Surg Oncol; 1993 Nov 15; 19(11):985-90. PubMed ID: 8245304
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Management of recurrent melanoma of the extremity.
    Shingleton WW, Seigler HF, Stocks LH, Downs RW.
    Cancer; 1975 Mar 15; 35(3):574-9. PubMed ID: 234293
    [Abstract] [Full Text] [Related]

  • 29. Malignant melanoma metastatic to the bladder. Regression following intratumor injection of BCG vaccine.
    Silverstein MJ, DeKernion J, Morton DL.
    JAMA; 1974 Aug 05; 229(6):688. PubMed ID: 4408302
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Effect of BCG (Tice strain) on primary sensitization to 2,4-dinitrochlorobenzene and on established delayed hypersensitivity in human malignant melanoma.
    Mavligit GM, Gutterman JU, Hersh EM.
    J Natl Cancer Inst; 1976 Oct 05; 57(4):749-51. PubMed ID: 1003526
    [Abstract] [Full Text] [Related]

  • 32. Systemic hypersensitivity reaction to intravesical BCG.
    Lyons D, Miller I, Jeffers A.
    Scott Med J; 1994 Apr 05; 39(2):49-50. PubMed ID: 8720760
    [Abstract] [Full Text] [Related]

  • 33. Feasibility study of active immunotherapy in patients with solid tumors.
    Gerner RE, Moore GE.
    Cancer; 1976 Jul 05; 38(1):131-43. PubMed ID: 779950
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. BCG immunotherapy in previously treated malignant melanoma patients.
    Mujagić H, Kolarić K, Malenica B, Nola P.
    Biomedicine; 1979 Jun 05; 30(2):95-102. PubMed ID: 476270
    [Abstract] [Full Text] [Related]

  • 36. Granulomas in melanoma patients treated with BCG immunotherapy.
    Hatzitheofilou C, Obenchain DF, Porter DD, Morton DL.
    Cancer; 1982 Jan 01; 49(1):55-60. PubMed ID: 7053820
    [Abstract] [Full Text] [Related]

  • 37. [Side effects of BCG immune therapy in 511 patients with malignant melanoma].
    Schult C.
    Hautarzt; 1984 Feb 01; 35(2):78-83. PubMed ID: 6706581
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Bacillus Calmette-Guerin injections for melanoma immunotherapy: potential for a false-positive PET/CT.
    Sogge SM, Fotos JS, Tulchinsky M.
    Clin Nucl Med; 2015 Apr 01; 40(4):368-9. PubMed ID: 25674877
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.